Statements (41)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Abb_Vie
|
| gptkbp:acquired |
gptkb:Allergan
|
| gptkbp:acquisition |
Allergan (2020)
|
| gptkbp:awards |
gptkb:Diversity_Inc_Top_50_Companies_for_Diversity
Best Places to Work Fortune 500 company Top Employer in Europe Top Employer in the U. S. |
| gptkbp:ceo |
gptkb:Richard_A._Gonzalez
|
| gptkbp:clinical_trial |
Phase 3 trials for Rinvoq
Phase 3 trials for Skyrizi Phase 1 trials for ABBV-181 Phase 2 trials for ABBV-181 |
| gptkbp:employees |
approximately 48,000
|
| gptkbp:focuses_on |
biopharmaceuticals
|
| gptkbp:founded |
gptkb:2013
|
| gptkbp:headquarters |
gptkb:North_Chicago,_Illinois
|
| https://www.w3.org/2000/01/rdf-schema#label |
ABBV
|
| gptkbp:partnership |
Abb Vie and the University of California, San Francisco
Abb Vie and Harvard University Abb Vie and the University of Chicago Abb Vie and the University of Michigan Abb Vie and the University of Pennsylvania |
| gptkbp:products |
gptkb:Humira
gptkb:Rinvoq gptkb:Skyrizi gptkb:Imbruvica |
| gptkbp:research_areas |
oncology
neuroscience immunology virology |
| gptkbp:revenue |
approximately $56 billion (2022)
|
| gptkbp:sustainability_initiatives |
commitment to diversity and inclusion
commitment to ethical business practices commitment to community engagement commitment to reducing greenhouse gas emissions commitment to responsible sourcing |
| gptkbp:traded_on |
gptkb:NYSE
|
| gptkbp:website |
www.abbvie.com
|